Yu gɛt Pɛriferal T-sɛl Limfoma (PTCL)? Nɔ wɔri, lɛ wi tɔk bɔt am!

Sɔntɛnde, wi kin gɛt sik dɛn we wi nɔ kin ivin tink bɔt, nɔto so? Pεrifεral T-sεl Limfoma, כ PTCL fכ sכt, na sכmtεm kכmplikεt kכndyushכn, bכt i rili imכtant fכ no am. I nɔr rili bi wan sik, bɔt na kɔmbayn sɔm sik dɛm. Wi go tɔk bɔt dis simpul wan, di we we yu go ɔndastand?

Pɛriferal T-sɛl Limfoma (PTCL) nɔto rili wan sik. Na wan grup we gɛt bɔku agresiv kayn blɔd kansa. Spɛshal wan, i kin afɛkt wi limfatik sistɛm . Yu kin dɔn yɛri bɔt am as ``Non-Hodgkin lymphoma'', ɛn na dat i bi. Wan tin bɔt PTCL na dat i kin skata (mɛtastaz) frɔm wan pat na di bɔdi to ɔda pat dɛn . Dis min se i kin afɛkt ɔlmost ɛni pat na di bɔdi, so di sayn dɛm kin difrɛn.

Di gud nyus na dat dɔktɔ dɛn kin ebul fɔ kɔntrol bɔku sɔbtayp dɛn fɔ PTCL fayn fayn wan. Bɔt sɔntɛnde, di sik kin kam bak . Na dat mek pipul dɛm wae de stɔdi bɔt mɛrɛsin kin de luk ɔltɛm fɔ nyu tritmɛnt dɛm wae kin ɛp pipul dɛm fɔ liv lɔng wit PTCL.

Dis sik we dɛn kɔl PTCL kɔmɔn?

Nɔ, dis nɔto rili kɔmɔn sik . Wan sɔv we dɛn du ɔlsay na di wɔl sho se na lɛk tu ɔndrɛd tawzin pipul dɛn kin gɛt PTCL. כlmost 10% pan di wan dεm we de divεlכp `(Non-Hodgkin lymphoma)` gεt PTCL.

Dɛn kin si dis sik smɔl smɔl na wi kɔntri dɛn na Eshia, Afrika, ɛn di Karibian pas Amɛrika. Bɔrku tɛm i kin kam pan pipul dɛm wae dɔn pas 60. Bɔt sɔm kayn kin kam bak pan yɔŋ pikin dɛm ɛn yɔŋ pipul dɛm .

Wetin na di men kayn PTCL?

Di Wol Wɛlbɔdi Ɔganayzeshɔn (WHO) dɔn no pas 20 sɔbtayp dɛn fɔ PTCL. Ɛni wan pan dɛn tin ya gɛt in yon spɛshal jɛnɛtik mak dɛn. Lɛ wi luk sɔm pan di kayn dɛn we pipul dɛn kin gɛt.

Pεrifεral T-sεl limfoma, we dεn nכ spεsifiket כda we (PTCL-NOS) .

Dis na di sɔbtayp we dɛn kin yuz mɔ . ``(PTCL-NOS)`` na kategori we inklud kes dεm we dεn nכ kin difayn prεsis εn we nכ fit insay di כda klia sכbtayp dεm. Na lɛk 30% pan ɔl di PTCL pasɛnt dɛn kin fɔdɔm insay dis kategori. I kin mɔs afɛkt yu limf no dɛm , bon mɛro, splin , ɔ liva .

Angioimyunoblastik T-sεl limfoma (AITL) .

Dis kin apin bak pan 15% to 30% pan PTCL pasɛnt dɛn ɔlsay na di wɔl. AITL kin afɛkt yu splin, bon mɛro, splin, ɔ liva bak.

Anaplastik big sɛl limfoma (ALCL) .

Difrɛn we dɛn de bak fɔ `(ALCL)`.

• Wan de we dɛn kɔl praymari cutaneous ALCL we de afɛkt di skin .
• Wan ɔda wan de.Sistem ALCL, we de afekt di lכng, skin, εn כda כgan dεm. dis sistεmik ALCL sכmtεm dεn kin klas am mכr bays pan chenj dεm na wan spεsifi k jin we dεn kכl ALK (anaplastic lymphoma kinase) . כlmost 15% pan di PTCL de fכl insay dis ``(ALCL)`` tכyp.

Ekstranodal natura kil/T-sεl limfoma, nos tכp

Dis wan spɛshal smɔl. dis sכbtayp kin divεlכp bכku tεm na di tisu dεm na yu nos , di sayn kכva dεm , εn di כp trot . Bɔt sɔntɛnde i kin go na di skin, di dijestiv trakt , ɛn ɔda pat dɛn. Dis kayn de mek lɛk 10% pan di PTCL.

Intestinal T-sεl limfoma dεm

Di nem sho am, nɔto so? Dis kin afɛkt di dijestiv sistɛm . I de mek lɛk 6% pan di PTCL. i gεt tכp dεm bak we dεn kכl εnteropati-asכsiet T-sεl limfoma (EATL) εn monomכrfik εpitεliotropik intestinal T-sεl limfoma (MEITL) .

Adult T-sɛl limfoma/lukimiya (ATLL) .

I kin afɛkt di skin ɛn di bon dɛn. Fo sכbtayp dεm de fכ ATLL: akyu, limfoma, krεse, εn smol smol . di tu kayn dεm we kin kכmכn pas כl na akyu εn lymphoma, we kin agresiv. Di kayn dɛn we nɔ de mɛn ɛn we de smok kin gro sloslo . εvri sכbtayp fכ ATLL de afekt difrεn pat dεm na di bכdi.

Wetin na di sayn dɛm fɔ PTCL?

Pan ɔl we ɛni sɔbtayp fɔ PTCL gɛt patikyula simptom dɛn, sɔm kɔmɔn wan dɛn de. Lɛ wi tek wan luk pan wetin dɛn bi:

• Di limf no dɛm we dɔn swel: Yu kin gɛt swel we nɔ de fil pen na yu nɛk, yu armpit, ɔ yu groin. Imajin wan smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl. Na dat.
• We yu nɔr ɛksplen: If yu lɔs lɛk 10% pan yu ɔl yu wet insay siks mɔnt, we yu nɔ tray tranga wan, na sɔntin we yu fɔ wɔri bɔt.
• Bɛlɛ pen ɔ swɛlin: Dis kin apin if yu splin dɔn big. Yu kin fil fayn, lɛk se yu bɛlɛ ful-ɔp.
• Taya ɔltɛm: Fɔ fil taya we nɔ kɔmɔn fɔ sɔm dez ɛn nɔ gɛt ɛni rizin. I tan lɛk se di taya nɔ de go ilɛksɛf yu slip bɔku.
• Fiva we dɛn nɔ ɛksplen: Bɔku tɛm, fiva kin apin we di bɔdi de fɛt wan infekshɔn. Bɔt if fiva we pas 39.5 digri sɛlshiɔs (103 Farenheit) kɔntinyu fɔ pas tu awa afta dɛn dɔn trit am na os, ɔ if di fiva kɔntinyu fɔ pas tu dez, dat kin bi sayn fɔ sɔntin we rili siriɔs.

De tin wae impɔtant pas ɔl na dat yu nɔr fɔ wɔri bɔt fɔ gɛt PTCL jɔs bikɔs yu gɛt dɛn sik ya. Dɛn kin bi bikɔs ɔf ɔda tin dɛn we simpul. Bɔt if dɛn sayn ya kɔntinyu, .I rili impɔtant fɔ rili go to dɔktɔ ɛn gɛt advays.

Naw lɛ wi si us sayn dɛm kin kam wit sɔm patikyula sɔbtayp dɛm in ad.

Atikul dεm fכ di pεriferal T-sεl limfoma, we dεn nכ spεsifiket כda we (PTCL-NOS) .

Apat frɔm di kɔmɔn sayn dɛm, yu kin si bak:

• di rεd bכdi sεl dεm we de dכn (Anemia) - Dis kin mek yu bכdi bכku εn taya bכku.
• di blכd pletlεt kכnt lכw (Thrombocytopenia) - Dis kin mek yu bכdi blכd.
• Rɛd spat dɛn we de it na di skin.
• If di kansa de na di chɛst , di chɛst de pen ɔ i nɔ izi fɔ blo (dyspnea).

כda tin dεm we de sho se di angioimmunoblastic T-sεl limfoma (AITL) .

Apat frɔm di kɔmɔn sayn dɛm:

• Nayt swet - Swet so we yu de slip dat di sheet dɛn kin wet.
• Skin rash we de rɔsh .
• כtoimyun dizכrd dεm lεk `(Autoimyun hεmolytic anemia) `.

Atikul dεm fכ anaplastik big sεl limfoma (ALCL) .

Primary cutaneous ALCL (di kayn we de afɛkt di skin) .

• Tin dεm lεk כnusual rεd כ rεdish-brawn diskכlareshכn na di skin, lumps we de big as tεm.
• Itch, big, rawnd blista dɛn .
• Dɛn bɔmp ya kin wund ɛn krɔst ɔva.

Sεstεmik ALCL (di kayn we de afekt di intanεt כgan dεm) .

Insay dis kes, dɛn kin si di simptom dɛm we kɔmɔn fɔ PTCL.

Ekstranodal natura kil/T-sεl limfoma, nos tכp

• Nasal congestion, na filin lɛk se di nos dɔn blok.
• Blɔd we de kɔmɔt na di nos .
• Di insay pat na di nos kin bi krɔs .
• Di fes we de swel wit pen .
• Ay prɔblɛm lɛk dischaj frɔm di yay ɛn yay pen.

Adult T-sɛl limfoma/lukimiya (ATLL) .

PTCL simptom dεm na kכmכn fכ כl di fכ sכbtayp dεm fכ ATLL.

Wetin na di tin dɛn we kin mek pɔsin gɛt PTCL?

fכ sכmtεm, Pεrifεral T-sεl limfoma de apin we di T sεl dεm na wi bכdi de mute (`(mutate)`) to kεnsar sεl dεm. As yu no, dɛn T sɛl ya na wan kayn wayt blɔd sɛl we de protɛkt wi frɔm tin dɛn we de kam insay wi lɛk jem dɛn we de kam insay wi bɔdi. So, we dɛn T sɛl ya chenj, dɛn kin bi kansa sɛl ɛn bigin fɔ bɔku we dɛn nɔ ebul fɔ kɔntrol . We dɛn bɔku lɛk dis, dɛn kin gɛda na wi lɔng, splin, liva, ɛn ɔda pat dɛn ɛn mek kansa tumbu dɛn .

di masta sabi pipul dεm stil nכ fכn wan difinitiv rizin we mek dεn T-sεl dεm ya de mute lεk dis.Bɔt, risach dɔn sho se i gɛt sɔntin fɔ du wit sɔm sik dɛn we pɔsin kin gɛt.

Fɔ ɛgzampul:

• Wan stɔdi we dɛn dɔn du na di wɔl dɔn sho se pipul dɛn we gɛt wan sik we dɛn kɔl celiac disease kin gɛt mɔ risk fɔ gɛt sɔm kayn PTCL, inklud ALCL.
• Dɔn bak, pipul dɛn we gɛt di Epstein-Barr vayrɔs kin gɛt mɔ risk fɔ gɛt ɛkstranodal natura kil/T-sɛl limfoma.
• Pipul dεm we gεt di vayrus `(Human T-cell lymphotropic virus Type 1 (HTLV-1))` de pan risk fכ divεlכp `(acute T-cell lymphoma/leukemia)`.

Aw dɛn kin no se pɔsin gɛt PTCL?

Dɔktɔ dɛn kin nid fɔ du sɔm difrɛn tɛst fɔ no di patikyula kayn PTCL we de mek yu gɛt wɛlbɔdi prɔblɛm. Dɛn tin ya kin bi blɔd tɛst, imej tɛst, bayɔpsi tɛst, ɛn jenɛtik tɛst fɔ stɔdi di jɛnɛtik we di kansa sɛl dɛn gɛt.

Blɔd tɛst dɛn

Dɔktɔ dɛn kin du blɔd tɛst fɔ chɛk fɔ si if dɛn gɛt vayrɔs dɛn we kin gɛt fɔ du wit PTCL. Dɛn tin ya kin bi:

• Kɔmplit blɔd kɔnt (CBC) .
• Komprεhεnsiv mεtabolik panεl (CMP) .
• Laktat dihaydrojɛnɛz (LDH) tɛst
• Epataytis B ɛn Epataytis C tɛst dɛn
• Yuman imyunodefisiɛns vayrɔs (HIV) tɛst
• Human T-sεl limfotropik vayrus Tayp 1 (HTLV-Tayp 1) tεst dεm

Test dɛn fɔ tek imej

Dɛn skan ya kin mek dɔktɔ dɛn ebul fɔ gɛt infɔmeshɔn bɔt di insay pat na yu bɔdi, mɔ usay di kansa dɛn de.

• Kɔmpyuta tomografi (CT) skan
• Pozitron emishɔn tomografi (PET) skan
• Magnɛtik rɛsɔnans imej (MRI) skan

Bayopsi dɛn we dɛn kin du

Dis min se dɛn kin tek wan smɔl pat pan di tisu frɔm wan say we dɛn kin tink se dɛn de tink ɛn chɛk am ɔnda maykroskɔp. Dis na di men we fɔ kɔnfɔm di sik klia wan .

• Limf node bayɔpsi
• Skin biopsy we dɛn kin du
• Bɔn mɛrɔ bayɔpsi

Wetin na di stej dɛm fɔ PTCL?

Dɔktɔ dɛn kin yuz kansa stej fɔ plan tritmɛnt ɛn gi yu aydia bɔt wetin yu kin ɛkspɛkt frɔm tritmɛnt (prognosis). dis stej de ditarmin bay di kayn PTCL εn usay di kεnsar T-sεl dεm dכn spre. Na di 4 men stej dɛm fɔ PTCL:

• Stej I: di kansa T-sεl dεm de כnli insay wan sεl כ wan kכlכsta sεl dεm.
• Stej II: Di kansa dɔn afɛkt tu ɔ mɔ limf no dɛm na di sem say na yu bɔdi (fɔ ɛgzampul, na ɛni say na yu nɛk, ɔ na di sem say ɔp ɔ dɔŋ di dayafragm).
• Stej III: Di kansa dɔn spre to di tisu dɛm we de ɔp ɛn dɔŋ yu dayafragm.
• Stej IV: Apat frɔm di tɛstikul, di kansa dɔn afɛkt ɔda pat dɛn bak lɛk di lɔng, liva, bon mɛro, ɔ di dijestiv sistɛm.

Wetin na di tritmɛnt dɛm fɔ PTCL?

Bikɔs bɔku sɔbtayp dɛn de fɔ PTCL ɛn di stej we di kansa de, no wan saiz tritmɛnt nɔ de . Di tritmɛnt we dɛn kin pik kin difrɛn frɔm wan pɔsin to ɔda pɔsin. Yu dɔktɔ go disayd di bɛst tritmɛnt fɔ yu. Na sɔm pan di tritmɛnt dɛn we dɛn kin yuz:

• Kimotɛrapi: Na difrɛn kayn kemotɛrapi mɛrɛsin dɛn we dɛn jɔyn togɛda. Dis na di men tritmɛnt wae dɛn kin yuse pas ɔl.
• Radiation therapy: Sɔntɛnde dɛn kin yuz dis wit kemotɛrapi, mɔ we di kansa de na di say we i de.
• Targeted therapy: Dis na tritmεnt wae de target spεshal jεnεtik chenj dεm (mכtεshכn) we de mek hεlty sεl dεm bi kεnsar sεl dεm. Dis difrɛn frɔm tradishɔnal kemotɛrapi.
• Kimotɛrapi ɛn allogeneic stem cell transplantation: Dɛn kin yuz dis tritmɛnt fɔ PTCL we nɔ de ansa to kemotɛrapi ɛn redyushɔn tɛrapi, ɔ we kin kam bak afta tritmɛnt. Dis na tritmɛnt we kɔmpleks smɔl.

Sɔntɛnde yu kin ebul fɔ tek pat pan klinik trial fɔ nyu tritmɛnt fɔ PTCL. Tɔk to yu dɔktɔ bɔt dis.

Wetin na di kɔmɔn sayd ɛfɛkt dɛm wae tritmɛnt kin gɛt?

Bɔku tritmɛnt dɛn fɔ kansa kin mek sɔm kayn bad bad tin dɛn apin. Bɔt nɔto ɔlman kin gɛt ɔl dɛn sayd ɛfɛkt ya, ɛn aw i kin tranga kin difrɛn. Fɔ ɛgzampul, di sayd ɛfɛkt dɛn we kemotɛrapi ɛn redyushɔn tɛrapi kin gɛt kin bi:

• Taya
• Kεmothεrapi-induced bren fכg - na filin fכ bren fכg, mεmכri lכs, εn difεlεnt fכ kכnsantreshכn.
• Nɔs ɛn vɔmit
• Di ia we de lɔs
• Sɔl dɛn na yu mɔt
• Mɔ kin gɛt infɛkshɔn

Naw, bɔku we dɛn de fɔ kɔntrol dɛn bad bad tin ya, so tɔk to yu dɔktɔ bɔt dat bak.

Wetin na di prɔgnosis fɔ PTCL?

Dis rili dipen pan di kayn PTCL, di stej we di kansa de, yu ɔl wɛl bɔdi, ɛn if di kansa de insay rɛmishɔn (``rɛmishɔn``) wit tritmɛnt.``Rɛmishɔn`` min se yu nɔ gɛt ɛni sayn ɛn yu nɔ go ebul fɔ fɛn ɛni sayn fɔ kansa pan tɛst. Sɔntɛnde, dɛn kin wɛl PTCL kɔmplit wan wit standad tritmɛnt dɛn.

כltu, bכku tכp dεm fכ pεriferal T-sεl limfoma kin kam bak (`(recur)`) . If dis apin, yu kin nid ɔda tritmɛnt ɔ ɔda kayn tritmɛnt.

Na nɔmal tin fɔ want fɔ no wetin fɔ ɛkspɛkt frɔm yu tritmɛnt. Yu dɔktɔ na di bɛst pɔsin fɔ no bɔt yu sik. So opin ɛn ɔnɛs wit am bɔt dis ɛn nɔ fred fɔ aks kwɛstyɔn.

Yu tink se dɛn kin ebul fɔ mek dɛn nɔ gɛt PTCL?

I sɔri fɔ no se, nɔ, as wi no, no patikyula we nɔ de fɔ mek dis nɔ apin . Dis limfoma kin kam bikɔs di T-sɛl dɛn nɔ de biev fayn ɛn dɛn kin gɛt kansa. Natin nɔ de we wi go du fɔ mek i nɔ apin. Bɔt fɔ avɔyd sɔm risk factor dɛm (e.g., di HTLV-1 vayrɔs) kin ridyus di risk fɔ divɛlɔp di kayn PTCL we gɛt fɔ du wit am.

Aw a kin kia fɔ misɛf? (Livin wit PTCL)

Pɛriferal T-sɛl limfoma na wan kayn kansa we nɔ kin bɔku ɛn we kin gro kwik kwik wan. If yu gɛt PTCL, na sɔm advays dɛn ya fɔ ɛp yu fɔ liv wit di sik:

• Tink bɔt palliative care: Dis kia kin ɛp yu fɔ kɔntrol di sayn dɛm ɛn di sayd ɛfɛkt dɛm we di tritmɛnt kin gɛt. Wetin pas dat, yu palliativ kia tim kin sɔpɔt yu fɔ dil wit de imɔshɔnal chalenj dɛm (sɔri, frayd, wɔri) wae kin kam wit liv wit dis kayn siriɔs sik.
• Fɛn sɔpɔt: Bikɔs PTCL na kansa wae nɔr kin bɔrku, yu kin fil lɛk na yu wan de dil wit am. Bɔt yu nɔ nid fɔ go am yu wan. Tɔk to yu mɛdikal tim ɛn fɛn ɔltin bɔt sɔpɔt grup dɛm usay yu kin kɔnɛkt wit ɔda pipul dɛm wae de go tru di sem tin lɛk yu. Fɔ sheb ɛkspiriɛns ɛn fɔ gɛt sɔpɔt frɔm ɔda pipul dɛn rili valyu dis tɛm.
• Tek tɛm fɔ yusɛf (Self-care): Kansa na tin wae de mek yu strɛs. Fɔ kia fɔ yusɛf rili impɔtant we yu de liv wit PTCL. Tɔk to yu wɛlbɔdi tim bɔt aw fɔ kɔntrol strɛs (mɛditeishɔn, ɛksesaiz fɔ blo, fɔ du sɔntin we yu lɛk fɔ du), ɛn aw fɔ mek it we gɛt fayn fayn it fɔ mek yu strɔng ɔl di tɛm we yu de trit yu. Gɛt inof slip.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

Nɔ fɔgɛt fɔ aks dɛn kwɛstyɔn ya we yu go si yu dɔktɔ:

• Us kayn Pɛriferal T-sɛl limfoma a gɛt? Wetin dɛn kɔl am?
• Wetin na di stej fɔ mi sik? Aw fa i dɔn skata?
• Us tritmɛnt opshɔn dɛn a gɛt? Wetin na di gud ɛn bad tin dɛn we ɛni tritmɛnt gɛt?
• Us kayn sakrifays dɛn kin ɛkspɛkt frɔm dɛn tritmɛnt ya?
• Wetin na di bad tin dɛn we kin apin we pɔsin gɛt tritmɛnt? Aw dɛn go ebul fɔ kɔntrol dɛn?
• A fɔ tink bɔt nyu tritmɛnt-based tritmɛnt (`(klinikal trial)`)? Dɛn rayt fɔ mi?
• Us chenj dɛn a nid fɔ mek na mi layf?

Faynal Mɛsej fɔ Tek-Hom

Pɛriferal T-sɛl limfoma (PTCL) na wan kayn blɔd kansa we nɔ kin bɔku bɔt we impɔtant. I kin apin we di T-sεl dεm we de protεkt wi bכdi de chenj εn bi kεnsar. Pan ɔl we dɛn gɛt di sem tin we kin mek dɛn gɛt dis sik, di we aw dɛn ɔl tu gɛt dɛn jɛnɛtiks difrɛn. Bikɔs PTCL kin afɛkt difrɛn pat dɛn na di bɔdi, sɔntɛnde i kin tranga fɔ no ɛn trit am.

Bɔt, kɔntinyu fɔ gɛt op! di mεdikal risach dεm de luk כltεm fכ nyu, mכr ifektiv tritmεnt dεm we de tכk bכt di jεnεtik chenj dεm na PTCL. If dɛn no se yu gɛt PTCL, nɔ panik, ɛn tɔk opin wan wit yu mɛdikal tim . Aks if nyu tritmɛnt dɛn de we dɛn kin du risach (klinik trial) we fit fɔ yu patikyula kɔndishɔn. If yu gɛt di rayt infɔmeshɔn ɛn di sɔpɔt we di wan dɛn we yu lɛk de gi yu, yu go gɛt pawa fɔ bia wit dis prɔblɛm!

` Pεrifεral T-sεl Limfoma, PTCL, Limfoma, T-sεl limfoma, Kεnsar, Blɔd kεnsar, Limfoma, PTCL simptom dεm, PTCL tritmεnt